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SYNOPSIS 
 
The incidence and significance of HER-2/neu gene amplification in esophageal adenocarcinoma 
is unknown.  Only 16% of esophageal adenocarcinoma patients had HER2 gene amplification, 
and its presence did not effect survival in this study.
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ABSTRACT 
 
Introduction:  HER-2/neu (c-erbB-2, HER2) gene amplification and protein overexpression 
have been associated with poor prognosis in several solid tumors, including breast and gastric 
cancer. Its incidence and significance in esophageal adenocarcinoma is unknown.  Methods:  
Tissue microarrays were successfully constructed from 89 paraffin-embedded archival specimens 
of esophageal adenocarcinomas for HER2 gene amplification by silver-enhanced in situ 
hybridization (SISH).  No patients had undergone neoadjuvant therapy.  Protein overexpression 
was tested with immunohistochemistry (IHC) using automated immunostaining (Ventana 
Benchmark).  Incidence of HER2 positivity, correlation to clinicopathological variables in 
esophageal cancer patients, and concordance between SISH and IHC were determined.  Results:  
True HER2 gene amplification was detected in 14 (16%) esophageal cancer specimens, and 92% 
of those with high-level HER2 amplification showed positive HER2 protein overexpression.  No 
significant associations were found among gene amplification and clinicopathological factors. 
Five-year survival rates were 57% for esophageal cancer patients with HER2 amplification 
compared to 32% without, but the difference in overall survival was not significant (P=0.37).  
The correlation between SISH and IHC was statistically significant (P<0.0001).  Conclusion:  
While molecular targeting may be possible for approximately 16% of esophageal 
adenocarcinoma patients, HER2 oncogene amplification did not influence survival in this study.
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INTRODUCTION 
 
Targeted molecular therapy in upper gastrointestinal cancer has become an increasingly popular 
topic over the past few years.  In part, this is due to rapid advances in our capability to 
characterize tumor biology.  Another consideration is our less-than-satisfactory ability to predict 
a particular tumor’s response to neoadjuvant therapy.  Esophageal adenocarcinoma is an example 
of an aggressive cancer in which only one third of patients present with resectable disease.  And 
of this select group, the average 5-year survival is only 35 to 45%.1  The addition of neoadjuvant 
therapy has significantly improved 5-year survivals, but much improvement is still needed.  
Targeted molecular therapy may help in this regard. 
 
Human epidermal growth factor receptor gene HER-2/neu (also known as c-erbB-2, now HER2) 
was recognized as an important prognostic factor in breast cancer in 1987.2,3  However, its role in 
other solid tumors is controversial.4-9  The published frequency of HER2 overexpression in 
esophageal cancer ranges from 11 to 73%.10  Reports evaluating its significance are also varied in 
their conclusions.  Nevertheless an international randomized Phase III trial, evaluating the 
survival benefit in gastric or gastro-esophageal junction cancer patients of the humanized anti-
HER2 monoclonal antibody (Trastuzumab), has just been published.11 
 
The aims of our study were 1) to determine the frequency of HER2 gene amplification and 
overexpression in esophageal adenocarcinoma; 2) to evaluate the association of HER2 gene 
amplification with patient and tumor characteristics and patient survival; and 3) to examine the 
correlation between amplification and expression of HER2 using silver-enhanced in situ 
hybridization (SISH) and immunohistochemistry (IHC).
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All patients who had undergone a surgical resection for invasive upper gastrointestinal 
adenocarcinoma were identified from an Adelaide-wide Esophageal Cancer Surgery audit 
database, held at the Royal Adelaide Hospital in Adelaide, Australia.  Since July 1997, 
prospective follow-up data has been collected and stored in this database.  Esophagectomy was 
performed by a 2-surgeon synchronous Ivor-Lewis technique via a right antero-lateral 
thoracotomy and an upper midline laparotomy, as described previously.12  A conservative lymph 
node dissection (removal of all nodes adjacent to the tumor) was performed in all patients, 
regardless of operative technique.13  Patients who underwent neoadjuvant therapy were 
excluded from this study to obtain a homogeneous cohort of patients in terms of treatment 
and to circumvent possible stage migration following chemoradiation therapy.  The study 





In a previous study1, we re-examined 240 esophageal cancer pathology specimens to determine 
which variables could improve the accuracy of the TNM staging system.  During this project, we 
also selected appropriate paraffin blocks for construction of tissue microarrays which were used 
in this study.  To increase our sample size, additional esophageal adenocarcinoma patients 
after January 2007 (up until December 2009) were included and appropriate paraffin 
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blocks were selected for review.  Specimen identification numbers were obtained from our 
database, and the designated paraffin blocks were then retrieved from one of 3 pathology 
laboratories:  ClinPath Laboratories, Institute for Medical and Veterinary Science, and Adelaide 
Pathology Partners.  Tissue microarrays were constructed with 2 cores, each 1.0 mm in diameter, 
from 2 paraffin blocks (i.e. 4 cores/patient).  Representative cores of tumor were selected by 
A.R.R. based on each block’s corresponding hematoxylin and eosin (H&E) stained sections.  
Other studies have demonstrated the reliability of tissue microarrays in the evaluation of HER2 
gene amplification in solid tumors including breast carcinomas.14 
 
Double-Staining for HER2 Amplification and AE1/AE3 Cytokeratin Expression 
 
Tissue microarray sections (4 µm) were cut, mounted on Superfrost Plus coated slides, labeled 
and then placed on a fully automated immunohistochemistry (IHC) staining and In Situ 
Hybridization (ISH) Ventana Benchmark XT (Roche Diagnostics) instrument.  The sections were 
incubated with ISH-protease 3 (Roche Diagnostics) for 8 min, washed with reaction buffer 
(Roche Diagnostics) followed by denaturation of tissue DNA at 95 °C.  The DNA probe for 
Human Epidermal Growth Factor Receptor 2 (HER2) (Roche Diagnostics), labeled with 
Dinitrophenol (DNP), was then added and hybridization occurred for 6 hours.  Rabbit anti-DNP 
(Roche Diagnostics) was used to detect the labeled probe followed by visualization with 
ultraView silver in situ hybridization (SISH) detection kit (Roche Diagnostics) in accordance 
with the manufacturer’s standard procedures.15 
 
The section was then washed in reaction buffer followed by addition of Cell Conditioning 1 
(CC1) solution (Roche Diagnostics) for 30 minutes.  CC1 was removed, washed, and the primary 
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mouse monoclonal epithelial antibody AE1/AE3 (Dako, Carpinteria, CA) for IHC was then 
added for 36 min whilst the slide was heated to 37°C.  The monoclonal antibody AE1/AE3 is 
widely used because it recognizes a broad range of keratin subtypes expressed in esophageal 
carcinomas.16  The ultraView™ Universal Alkaline Phosphatase RED kit (Roche Diagnostics), 
used in accordance with the manufacturer’s recommendations, was used to detect the location of 
the primary antibody AE1/AE3 followed by counterstaining with hematoxylin 11 (Roche 
Diagnostics). 
 
Evaluation of HER2 Gene Amplification 
 
Evaluation of SISH hybridization was performed with conventional light microscopy by a 
histopathologist (A.R.R.) and a medical scientist (R.D.).  Both were blinded with respect to 
patient identification, tumor characteristics on conventional histopathology, and HER2 
protein expression.  Gene amplification was assessed as per the Australian HER2 Advisory 
Board criteria for single HER2 probe testing:  diploid = 1 to 2.5 copies/nucleus in more than 50% 
of tumor cells; polysomy = 2.5 to 4 copies/nucleus in more than 50% of tumor cells; equivocal 
amplification = >4 to 6 copies/nucleus in more than 50% of tumor cells; low-level amplification 
= 6 to 10 copies/nucleus in more than 50% of tumor cells; high-level amplification = >10 
copies/nucleus in more than 50% of tumor cells.  When using the Chromosome 17 probe, the 
classification of not amplified was when the HER2/Chromosome 17 ratio was <1.8; equivocal 
>1.8 and <2.2; and amplification was >2.2.  HER2 and Chromosome 17 assays were performed 
on contiguous sections allowing for the identification and exclusion of chromosome 17 
polysomy.2,15 
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Staining for HER2 Protein with Immunohistochemistry 
 
Sections (4 µm) of tissue microarrays were cut, mounted on coated slides, labeled, and then 
placed on the Ventana Benchmark XT (Roche Diagnostics) for detection of the HER2 
oncoprotein.  The sections were de-waxed then subjected to pre-treatment with CC1 for 30 
minutes.  Sections were then washed with reaction buffer followed by incubation with the rabbit 
monoclonal primary antibody HER-2/neu (Clone 4B5, Roche Diagnostics) for 28 minutes.  On 
board detection using ultraView™ Universal DAB kit (Roche Diagnostics), used in accordance 
with the manufacturer’s recommendations, was used to detect the location of the primary 
antibody HER2 followed by counter stain with hematoxylin 11 (Roche Diagnostics). 
 
Evaluation of HER2 Protein Expression 
 
Evaluation and scoring of HER2-protein expression was performed according to the Dako 
HercepTestTM scoring system for breast cancer.  This scoring system has been validated for use in 
gastric cancer with minor modifications:3,17  0/negative = staining or membranous reactivity in 
<10% of cells; 1+/negative = faint membranous reactivity in >10% of cells or cells with 
reactivity only in part of their membrane; 2+/equivocal = weak/moderate complete or basolateral 
membranous staining in >10% of tumor cells; 3+/positive = strong complete or basolateral 
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The presence of HER2 gene amplification and/or protein overexpression was correlated with 
clinical outcome.  Overall survival was calculated from the date of operation to July 15, 2010 (if 
alive) or to the date of death (as recorded from the South Australian Cancer Registry) according 
to the Kaplan-Meier method.  Fisher’s exact tests were used to compare variables between 
the two HER2 amplification groups (present/not present).  Survival was compared between 
the groups using a log rank test.  Differences in survival between the HER2 groups were assessed 
using a log-rank test.  Correlation between SISH and immunohistochemistry was calculated using 
the Kendall Tau-b correlation coefficient.18  Statistical significance was set at the 5% level.  
Calculations were performed using SAS Version 9.2 (SAS Institute Inc., Cary, NC, USA).





There were 336 patients who underwent a surgical resection for esophageal cancer between July 
1997 and December 2009 identified from the database.  The 30-d mortality rate was 4.8%.  Of 
these, 140 met inclusion criteria of an esophageal adenocarcinoma and no chemoradiotherapy 
prior to surgical resection.  A further 51 patients were excluded for various reasons, and we were 
left with a study population of 89 patients (Figure 1). 
 
Patients’ and tumor characteristics are listed in Table 1.  The mean age was 63.9 years (95% CI 
61.7-66.1 years).  There were 74 men (83%) and 15 women (17%).  The median time of patient 
follow-up was 20.6 months (627 days).  Complete follow-up was available for all 89 patients 
with an overall 5-year survival rate of 35%, and a median survival of 22.1 months. 
 
HER2 Amplification or Overexpression 
 
Fourteen esophageal cancer patients had HER2 gene amplification (Figure 2).  Similar numbers 
of patients had weak/moderate or strong membrane staining for HER2 protein overexpression 
(Table 2).  HER2 amplification was seen more commonly in pT1 (25%) and pT4 tumors 
(27%) versus pT2 (9%) and pT3 (11%) tumors but this difference was not significant 
(P=0.25).  The presence of low or high HER2 amplification did not influence any other patient or 
tumor characteristic (Table 3).  Five-year survival rates were 57% (median, 68.9 months) for 
esophageal cancer patients with HER2 amplification compared to 32% (median, 20.6 
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months) without, but the difference in overall survival was not significant (P=0.37) (Figure 
3).  Similarly, in the Barrett’s cancer subset of patients, there was no significant difference in 
overall survival between groups (P=0.29). 
 
Correlation between HER2 Amplification and Overexpression 
 
When SISH results were compared with HER2 immunohistochemical (IHC) data, eleven of 
twelve cases (92%) with high-level gene amplification showed positive 3+ protein expression 
(Table 4).  The remaining case was negative for protein expression.  One of two low-level gene 
amplification cases was equivocal (2+) on IHC testing, while the other was negative (1+).  None 
of the diploid nor Polysomy 17 cases showed equivocal or positive protein expression.  We did 
not classify any cases in the equivocal category for HER2 amplification using SISH.  Overall, 
there was a significant correlation between SISH and immunohistochemistry for HER2 gene 
amplification and expression (P<0.0001).  The correlation coefficient between SISH and IHC 
was 0.636 (moderate/strong association) (P<0.0001).
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DISCUSSION 
 
Close to 16% of our esophageal cancer patients had HER2 gene amplification and overexpression 
in their primary tumor.  The previously quoted range of 11-73% for HER2 overexpression largely 
originates from studies conducted in the 1990s, and using primarily immunohistochemistry.19-25  
Some of these older studies concluded that HER2 protein overexpression corresponds with poor 
survival.19,20  But more recently, studies have examined the frequency of HER2 gene 
amplification in esophageal adenocarcinoma at the DNA level using either polymerase 
chain reaction (PCR) or some form of in-situ hybridization (ISH).7,10,26-29  Our results 
correspond to these latter studies (except one26 with a small sample size of 25) in which 
frequencies of HER2 amplification are consistently lower and range from 12-24%. 
 
Unlike one study in esophageal adenocarcinoma10, upon which current Herceptin-based trials 
seem to be based, we found no correlation between the presence of HER2 amplification and 
patient survival.  Nor was there any correlation between HER2 amplification and 
clinicopathological factors.  Brien et al evaluated HER2 amplification with FISH in 63 Barrett’s 
adenocarcinoma patients, and although they found no significant association between HER2 
amplification and clinicopathological factors, they reported a significant association between its 
presence and poorer survival.10  However, in this study, a low threshold of 4 or more signals 
(rather than the currently accepted threshold of 6 or more signals15) per nucleus was used to 
determine the presence of HER2 amplification.10  In addition, patients with chromosome 17 
polysomy were not excluded.  Aneuploidy of chromosome 17, usually involving an increase in 
the number of chromosomal copies (i.e. polysomy), has been reported in approximately one third 
of breast cancers.  However, increased protein expression at the significant 3+ level does not 
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seem to result from this mechanism because HER2 appears to remain normally regulated.26  
Some investigators have suggested that controversy regarding the role of HER2 amplification and 
its affect on survival might be explained by the failure to distinguish between true HER2 gene 
amplification and chromosome 17 polysomy.26,30 
 
In esophageal adenocarcinoma at least, our results seem to be the norm rather than the 
exception.22-25,27,29  The lack of any apparent effect of HER2 amplification on patient 
survival is supported by the absence of any association between HER2 amplification and 
known poor prognostic pathological factors (i.e. pT-stage, pN-stage).  Results of the ToGA 
(Trastuzumab for Gastric Cancer) trial suggested that HER2-positive patients with 
junctional gastro-esophageal cancers were potential responders to anti-HER2 monoclonal 
antibody-based therapy.11  However, even the authors of this trial point out that the 
survival benefit seen in the HER2-positive group may have been due to the presence of 
HER2 overexpression alone rather than the result of HER2-targeted therapy. 
 
Support for HER2 amplification as a prognostic and predictive factor in gastric adenocarcinoma 
is also controversial with several studies showing a significant association31, and others not.32  
The most recent of these encompassed 924 gastric cancer cases and is the largest study to date 
showing that HER2 expression is not related to patient prognosis.33  Unfortunately, the authors 
did not confirm their results with in situ hybridization techniques.  Similarly, the importance of 
HER2 amplification and expression in esophageal squamous cell carcinoma remains unclear.  
Soares et al found that 37% of patients were HER2-positive with immunohistochemistry, while 
only 19% of these were HER2-positive by FISH criteria.  Those positive on FISH were shown to 
have significantly poorer survival.5  However, Gibault et al reported overexpression of HER2 in 
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only 2.8% of patients with esophageal squamous cell cancer, and they concluded that HER2 
“appears to be of poor interest” as a potential therapeutic target in this type of esophageal 
cancer.34 
 
Aside from methodological factors (discussed in greater detail below), we may not have found a 
survival advantage in HER2-negative cases due to the clonal divergence of primary tumors and 
disseminated tumor cells (DTCs).  Klein et al recently reported that HER2 gene amplification 
was not conserved between primary tumors and DTCs (i.e. neither the presence nor absence of 
HER2 amplification in the primary tumor was predictive for the HER2 status in DTCs of the 
same patient).  More importantly, they found that HER2 amplification in the primary tumor did 
not affect survival, while HER2 amplification in DTCs led to significantly shorter survival 
suggesting an increased dependence on HER2 signaling in the latter group.35  This too is 
controversial however with Reichelt et al reporting the opposite finding.27  They found 
perfect correlation of HER2 amplification using FISH between the primary tumor and 
lymph node/distant metastases, and no effect on overall survival.  
 
There are several limitations to our study.  Perhaps foremost, our negative findings may relate 
to sample size (type II statistical error).  Our initial submission to the journal described the 
results of 70 esophageal adenocarcinoma patients.  We reported a P value of 0.06 when 
comparing survival rates between those with HER2 amplification and those without (67% 
vs. 28%, respectively).  Upon request by the journal, we re-analyzed failed SISH specimens 
in an attempt to increase our sample size.  With a new total of 89 patients, we found similar 
differences in survival (57% with HER2 amplificaiont vs. 32% without) but a much less 
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convincing P value of 0.37 suggesting that HER2 amplification has no influence on survival 
(at least in the negative sense).  
 
Second, it is possible that by excluding patients who received neoadjuvant therapy, we 
created a selection bias favoring less advanced tumors.  However, 65% of the patients in 
our study had advanced tumors (pT3 or pT4) due to the more infrequent use of 
neoadjuvant therapy in the late 1990s.  And in our previous study1, we found no significant 
difference in survival between 116 patients treated with surgery alone, and 124 patients 
treated with neoadjuvant therapy and surgery (5-year survival rates of 31% vs. 41%, 
respectively) (P=0.125).  Further studies are needed which include patients who have 
received neoadjuvant therapy as well as those with metastatic disease. 
 
As stated above, many prior studies have used immunohistochemistry (IHC) alone to determine 
HER2 expression in upper gastrointestinal cancer.  However, IHC is susceptible to inter-observer 
variability and variations in testing protocols (such as insufficient or prolonged formalin 
fixation).2,29  As well, a number of studies in breast cancer have indicated that gene amplification 
is a more accurate predictor of survival than gene expression.31,36  Fluorescence in situ 
hybridization (FISH) was included in the diagnostic algorithms for HER2 positivity in breast 
cancer to reduce inter-observer error and confirm cases with equivocal HerceptTest staining (2+).  
However, FISH is a costly technology requiring both a fluorescence microscope and digital 
photography, and fluorescent signals will deteriorate over a few weeks.2,31  In addition, a recent 
study by Rauser et al highlighted the unreliable detection of low-level HER2 amplification in 
Barrett’s cancer using standard FISH in thin (4 μm) tissue sections.37 
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Bright-field in situ hybridization such as silver-enhanced in situ hybridization (SISH) used in our 
study is gaining popularity as it requires only a light microscope, and it is fully automated and 
rapidly performed.  Staining remains stable for a long period and it is relatively easy to interpret.2 
An additional advantage over chromogenic in situ hybridization (CISH) is that HER2 and 
chromosome 17 assays can be performed on contiguous slides allowing for exclusion of 
polysomy rather than locus-specific amplification.2,31  High concordance has been found between 
FISH and SISH in breast cancer studies (>95%), and high inter-observer concordance exists with 
SISH (93-95%).2,36  We found high concordance between IHC and SISH in this study.
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CONCLUSION 
 
HER2 gene amplification and overexpression was present in 16% of esophageal 
adenocarcinomas.  It did not appear to influence survival.  Although a subset of esophageal 
adenocarcinoma patients may meet the criteria for anti-HER2 monoclonal antibody therapy, it is 
too early to suggest that such therapy may decrease disease-free recurrence rates and increase 
long-term survival.  Future studies should employ reproducible methodology using in situ 
hybridization techniques.  As well, research into targeted molecular therapies will have to take 
into account characteristics of both the primary tumor and disseminated tumor cells. 
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FIGURE LEGENDS 
 
Figure 1.  Study population. 
 
Figure 2.  Formalin-fixed, paraffin-embedded esophageal adenocarcinoma tissue microarrays.  
Representative specimen (a, hematoxylin & eosin stain) showing no HER2 protein expression (b, 
AE1/AE3 immunohistochemical stain), and no HER2 gene amplification (c, silver-enhanced in 
situ hybridization).  Second example (a, hematoxylin & eosin stain) showing 3+/positive HER2 
protein expression (b, AE1/AE3 immunohistochemical stain), and high-level HER2 gene 
amplification (c, silver-enhanced in situ hybridization). 
 
Figure 3.  Overall 5-year survival according to the presence or absence of HER2 gene 
amplification for 89 patients who underwent surgical resection of esophageal adenocarcinoma.  
Although there was a difference in 5-year survival rates between these 2 groups : 57% vs. 32%, it 
was not significant (P=0.37). 
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Table 1.  Patient and tumor characteristics 
 
Variable      Esophageal Cancera 
       (n=89) 
   
Age, y 
 < 70       58 (65) 
 > 70       31 (35) 
Sex 
 Male       74 (83) 
 Female      15 (17) 
Tumor location 
 Lower 1/3 esophagus     23 (26) 
 GOJb      66 (74) 
Grade of differentiation 
 Well/moderate (G1 + G2)    26 (29) 
 Poor/undifferentiated (G3 + G4)    61 (69) 
 Unknown        2 (2) 
pT-stage  
 T1        20 (23) 
 T2        11 (12) 
 T3        47 (53) 
 T4        11 (12) 
pN-stage 
 N0        37 (42) 
 N1        52 (58) 
pM-stage 
 M0       86 (97) 
 M1         3 (3) 
Stage groups (UICC 2002)c 
 I        19 (21) 
 IIA       17 (19) 
 IIB          5 (6) 
 III        45 (51) 
 IV          3 (3) 
Radial margin 
 Negative      43 (48) 
 Positive      45 (51) 
 Not assessable       1 (1) 
Vascular invasion 
 No        24 (27) 
 Yes       64 (72) 
 Unknown        1 (1) 
Perineural invasion 
 No        37 (42)  
 Yes       43 (48) 
 Unknown        9 (10) 
Barrett’s oesophagus 
 No        38 (43) 
 Yes       51 (57) 
 
aEsophageal cancer : all adenocarcinoma 
bGOJ = gastro-esophageal junction 
cStage I: T1N0M0; Stage IIA: T2-3N0M0; Stage IIB T1-2N1M0; Stage III: T3N1M0/T4anyNM0; Stage IV: anyTanyNM1
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Table 2.  Incidence of HER2/neu amplification and immunohistochemical expression in 
esophageal adenocarcinoma 
 
       Esophageal cancer 
         (n = 89) 
   
Gene amplificationa 
 No amplification       53 (59.5) 
 Polysomy 17        22 (25) 
 Low amplification         2 (2) 
 High amplification       12 (13.5) 
 
Immunohistochemical expressionb 
 0          63 (71) 
 CY         14 (16) 
 1+            1 (1) 
 2+          11 (12) 
  
aNo amplification = <2.5 signals/nucleus; polysomy 17 = 2.5-5 signals/nucleus; low amplification = 6-10 
signals/nucleus; high amplification = >10 signals/nucleus 
b0 = no staining; CY = cytoplasmic staining; 1+ = weak/moderate complete membrane staining; 2+ = strong 
complete membrane staining 
HER2 in Esophageal Cancer   26 
 
 
Table 3.  Association between patient and tumor characteristics and HER2/neu 
amplification in esophageal adenocarcinoma (n = 89) 
 
     No. Patients  HER2/neu + 
Variable       n (%)   P value 
   
Age, y 
 < 70     58   7 (12)   0.23 
 > 70     31   7 (23) 
Sex 
 Male     74   12 (16)   1.0 
 Female    15   2 (13) 
Tumor location 
 Lower 1/3 esophagus   23   2 (9)   0.51 
 GOJa    66   12 (18) 
Grade of differentiation 
 Well/moderate (G1 + G2)  26   4 (15)   1.0 
 Poor/undifferentiated (G3 + G4)  61   9 (15) 
 Unknown    2   1 (50) 
pT-stage  
 T1      20   5 (25)   0.25 
 T2      11   1 (9) 
 T3      47   5 (11) 
 T4      11   3 (27) 
pN-stage 
 N0      37   5 (14)   0.77 
 N1      52   9 (17) 
pM-stage 
 M0     86   13 (15)   0.41 
 M1     3   1 (33) 
Stage groups (UICC 2002)b 
 I      19   4 (21)   0.48 
 IIA     17   1 (6) 
 IIB      5   1 (20) 
 III      45   7 (16) 
 IV      3   1 (33) 
Radial margin 
 Negative    43   7 (16)   1.0 
 Positive    45   7 (16) 
 Not assessable   1   0 (0) 
Vascular invasion 
 No      24   5 (21)   0.33 
 Yes     64   8 (13) 
 Unknown    1   1 (100) 
Perineural invasion 
 No      37   7 (19)   0.53 
 Yes     43   5 (12) 
 Unknown    9   2 (22) 
Barrett’s oesophagus 
 No      38   6 (16)   1.0 
 Yes     51   8 (16) 
 
aGOJ = gastro-esophageal junction 
bStage I: T1N0M0; Stage IIA: T2-3N0M0; Stage IIB T1-2N1M0; Stage III: T3N1M0/T4anyNM0; Stage IV: anyTanyNM1 
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Table 4.  Comparative data for SISH HER-2/neu gene copy status and HER-2 IHC 
(amended HercepTest) in esophageal adenocarcinoma 
   IHCa 0  IHC 1+  IHC 2+  IHC 3+  
(n=63)  (n=14)  (n=1)  (n=11) 
Diploid (n = 53)    44  9  0  0 
Polysomy 17 (n = 22)   18  4  0  0 
Low amplification (n = 2)  0  1  1  0 
High amplification (n = 12)  1  0  0  11 
 
 
SISH = silver in situ hybridization; IHC = immunohistochemistry 
a0 = negative, 1+= faint or incomplete membrane staining; 2+ = weak/moderate membranous staining; 3+ = strong 
membranous staining 
